Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 15/20 | 0.86 |
| ▸ | NTRK2 | Q16620 | 15/20 | 0.86 |
| ▸ | IGF1R | P08069 | 5/20 | 0.86 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.86 |
| ▸ | NTRK3 | Q16288 | 11/20 | 0.65 |
| ▸ | BCAT1 | P54687 | 3/20 | 0.42 |
| ▸ | BCAT2 | O15382 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30744039 | 1.00 | NTRK1 (0.86) | NTRK1NTRK2IGF1RFGFR1NTRK3 | |
| SCHEMBL21295407 | 0.93 | NTRK1 (1.00) | NTRK1NTRK2IGF1RFGFR1NTRK3 | |
| SCHEMBL30743942 | 0.93 | NTRK1 (0.95) | NTRK1NTRK2IGF1RFGFR1NTRK3 | |
| SCHEMBL21305495 | 0.93 | NTRK1 (0.95) | NTRK1NTRK2IGF1RFGFR1NTRK3 | |
| SCHEMBL21295434 | 0.90 | NTRK1 (0.90) | NTRK1NTRK2IGF1RFGFR1NTRK3 | |
| SCHEMBL23051394 | 0.88 | NTRK1 (0.86) | NTRK1NTRK2IGF1RFGFR1NTRK3 | |
| SCHEMBL29625913 | 0.88 | NTRK1 (0.86) | NTRK1NTRK2IGF1RFGFR1NTRK3 | |
| SCHEMBL23051395 | 0.86 | NTRK1 (0.86) | NTRK1NTRK2IGF1RFGFR1NTRK3 | |
| SCHEMBL21295396 | 0.86 | NTRK1 (0.86) | NTRK1NTRK2IGF1RFGFR1NTRK3 | |
| SCHEMBL30743944 | 0.86 | NTRK1 (0.86) | NTRK1NTRK2IGF1RFGFR1NTRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250214948-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | AlzeCure Pharma AB (SE) | 2025-07-03 | — | — | US | claimed |
| EP-3759088-B1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | AlzeCure Pharma AB (SE) | 2023-01-25 | — | — | EP | claimed |
| US-20250214948-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | AlzeCure Pharma AB (SE) | 2025-07-03 | — | — | US | disclosed |
| CN-111819172-B | Triazine derivatives for the treatment of neurotrophin related diseases | 阿泽克制药公司 | 2024-02-06 | — | — | CN | disclosed |
| EP-3759088-B1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | AlzeCure Pharma AB (SE) | 2023-01-25 | — | — | EP | disclosed |
| US-20220306589-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | AlzeCure Pharma AB (SE) | 2022-09-29 | — | — | US | disclosed |
| US-11352332-B2 | Triazine derivatives for treating diseases relating to neurotrophins | AlzeCure Pharma AB (SE) | 2022-06-07 | — | — | US | disclosed |
| US-11352332-B2 | Triazine derivatives for treating diseases relating to neurotrophins | AlzeCure Pharma AB (SE) | 2022-06-07 | — | — | US | disclosed |
| EP-3759088-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | Alzecure Pharma AB (SE) | 2021-01-06 | — | — | EP | disclosed |
| US-20200399230-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | AlzeCure Pharma AB (SE) | 2020-12-24 | — | — | US | disclosed |
| US-20200399230-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | AlzeCure Pharma AB (SE) | 2020-12-24 | — | — | US | disclosed |
| CN-111819172-A | Triazine derivatives for the treatment of neurotrophin-related disorders | 阿泽克制药公司 | 2020-10-23 | — | — | CN | disclosed |
| WO-2019162702-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | AlzeCure Pharma AB (SE) | 2019-08-29 | — | — | WO | disclosed |
| WO-2019162702-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | AlzeCure Pharma AB (SE) | 2019-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220306589-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | NTRK2, BDNF, NGF | NTRK1 15/4885NTRK2 1/4885IGF1R 127/4885 |
| US-20250214948-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | NTRK2, BDNF, NGF | NTRK1 15/4885NTRK2 1/4885IGF1R 127/4885 |
| US-11352332-B2 | Triazine derivatives for treating diseases relating to neurotrophins | NTRK2, BDNF, NGF | NTRK1 13/4885NTRK2 1/4885IGF1R 83/4885 |
| US-20200399230-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | NTRK2, BDNF, NGF | NTRK1 13/4885NTRK2 1/4885IGF1R 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.